Globally, gene and cell therapy is moving from frontier research to large-scale industrial application. Major economies have successively incorporated it into strategic emerging industry plans with systematic support in approval, payment and R&D funding.
As technology costs keep falling and clinical evidence accumulates, industry standardization is accelerating, making quality control, cold-chain logistics and digital traceability key parts of industrial infrastructure.
The arrival of the standardization era raises higher requirements for companies' technical depth and systematic capabilities.
